MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating
MoonLake Immunotherapeutics Announces Virtual Capital Markets Day on April 29, 2025, to Discuss Financial and Clinical Milestones
MoonLake Immunotherapeutics to Host a Capital Markets Day on Tuesday, April 29
Catalyst Watch: Apple, Amazon & Microsoft's Earnings Confessions, Meta's LlamaCon and the Jobs Report
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $77
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Good Position To Deliver On Growth Plans
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
